A Phase 2 study of venetoclax, a new drug for chronic lymphocytic leukaemia (CLL), has shown a clinically meaningful reduction in cancer cells in patients with a specific genetic mutation known as the 17p deletion. The patients all had refractory CLL.
Interim results from a Phase 3 trial in Guinea of a candidate vaccine against the Ebola virus have shown the agent to be safe and effective within six to 10 days of vaccination. The trial data were announced by Merck & Co Inc and published online in The Lancet on 31 July.
A new company has been set up in the UK to acquire clinical assets that large pharma companies may not be in a position to develop further. The first programmes acquired by Mereo BioPharma Group Ltd are three mid-stage clinical assets from Novartis.
A second drug being developed by Roche for Alzheimer’s disease has failed an efficacy test – this time in a Phase 2b trial. The drug, sembragiline (RG1577, EVT302), is an inhibitor of an enzyme that contributes to the production of free radicals, which contribute to the disease’s pathology.
Eli Lilly and Company and Immunocore Ltd have agreed to test two potential combination therapies for the treatment of melanoma that involve Immunocore’s T cell receptor technology together with two of Lilly’s experimental kinase inhibitors.
Allergy Therapeutics Plc has outlined plans for the resumption of US clinical trials of its short-course vaccine against grass allergy, Pollinex Quattro Grass, following the submission of trial protocols to the Food and Drug Administration, and new funding.
Silence Therapeutics Plc of the UK has confirmed that patients with incurable pancreatic cancer benefited from treatment with its RNA interference (RNAi) compound, which works by silencing a gene linked to a protein responsible for cancer metastases.
The Netherlands-based cell therapy company Kiadis Pharma BV is planning an initial public offering (IPO) of its shares on the Euronext stock exchanges in Amsterdam and Brussels to finance the clinical development of a cell therapy that helps reconstitute the immune system after a bone marrow transplant.
Amgen Inc and Roche have decided to jointly conduct human trials in a prospective immunotherapy for cancer that combine’s Amgen’s oncolytic vaccine talimogene laherparepvec (T-VEC)) with Roche’s checkpoint inhibitor atezolizumab.
Patients with one of four subtypes of non-Hodgkin’s lymphoma have shown a response to treatment with a CD-19 antibody called MOR208 which was administered as a monotherapy. Data from the Phase 2a study also showed the drug was well tolerated, according to the developer MorphoSys AG.